Clinical Trial Update: Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating glofitamab as a bridging therapy to autologous stem cell transplantation for patients with relapsed or refractory diffuse large B-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Diffuse Large B-cell Lymphoma(DLBCL) | Phase 2 | Status: RECRUITING